CIK 0001937653 · Non-accelerated filer<br>Smaller reporting company
Zymeworks Inc.
Sign in to watch- Ticker
- ZYME
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 883099146
- Phone
- 302-274-8744
- Business address
- 108 PATRIOT DRIVE, SUITE A, MIDDLETOWN, DE, 19709
- Former names
- Zymeworks Delaware Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $357,557
- in 1 filing
Net −$357,557. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-10 | PATTERSON LEONE D EVP, Chief Bus & Fin Officer | Grant or award · Stock Option (Right to Buy) | +79,000 | 79,000 | ||
| 2025-01-10 | PATTERSON LEONE D EVP, Chief Bus & Fin Officer | Grant or award · Restricted Stock Unit | +53,000 | 53,000 | ||
| 2025-01-10 | Moore Paul Andrew Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +79,000 | 79,000 | ||
| 2025-01-10 | Moore Paul Andrew Chief Scientific Officer | Grant or award · Restricted Stock Unit | +53,000 | 53,000 | ||
| 2025-01-10 | Smith Jeffrey T L EVP & Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +79,000 | 79,000 | ||
| 2025-01-10 | Smith Jeffrey T L EVP & Chief Medical Officer | Grant or award · Restricted Stock Unit | +53,000 | 53,000 | ||
| 2025-01-10 | Galbraith Kenneth Chair & CEO | Grant or award · Stock Option (Right to Buy) | +288,000 | 288,000 | ||
| 2025-01-10 | Galbraith Kenneth Chair & CEO | Grant or award · Restricted Stock Unit | +192,000 | 192,000 | ||
| 2025-01-10 | EcoR1 Capital, LLC Director | Purchase | +204,098 | $13.13 | $2.7M | 15,411,078 |
| 2025-01-08 | EcoR1 Capital, LLC Director | Purchase | +21,021 | $14.07 | $296K | 15,206,980 |
| 2025-01-06 | Moore Paul Andrew Chief Scientific Officer | Option exercise | +17,166 | 24,533 | ||
| 2025-01-06 | Moore Paul Andrew Chief Scientific Officer | Sale | −9,792 | $14.92 | $146K | 14,741 |
| 2025-01-06 | Moore Paul Andrew Chief Scientific Officer | Option exercise | +20,000 | 34,741 | ||
| 2025-01-06 | Moore Paul Andrew Chief Scientific Officer | Sale | −11,408 | $14.92 | $170K | 23,333 |
| 2025-01-06 | Moore Paul Andrew Chief Scientific Officer | Option exercise · Restricted Stock Unit | −17,166 | 17,168 | ||
| 2025-01-06 | Moore Paul Andrew Chief Scientific Officer | Option exercise · Restricted Stock Unit | −20,000 | 40,000 | ||
| 2025-01-06 | Galbraith Kenneth Chair & CEO | Option exercise | +47,666 | 71,428 | ||
| 2025-01-06 | Galbraith Kenneth Chair & CEO | Sale | −23,885 | $14.92 | $356K | 47,543 |
| 2025-01-06 | Galbraith Kenneth Chair & CEO | Option exercise | +66,666 | 114,209 | ||
| 2025-01-06 | Galbraith Kenneth Chair & CEO | Sale | −33,406 | $14.92 | $499K | 80,803 |
Page 6 of 12 · 224 trades